Palvella Therapeutics, Inc. Income Tax Expense
Palvella Therapeutics, Inc. (PVLA) reported Income Tax Expense of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-08-04
- Palvella Therapeutics, Inc. income tax expense (benefit) for the quarter ending 2026-06-30 was $0.00.
- Palvella Therapeutics, Inc. income tax expense (benefit) for the quarter ending 2026-03-31 was $0.00.
- Palvella Therapeutics, Inc. income tax expense (benefit) for the quarter ending 2025-12-31 was $0.00.
- Palvella Therapeutics, Inc. income tax expense (benefit) for the quarter ending 2025-09-30 was $0.00.
- Palvella Therapeutics, Inc. income tax expense (benefit) for fiscal 2025 was $0.00.
- Palvella Therapeutics, Inc. income tax expense (benefit) for fiscal 2024 was $0.00.
- Palvella Therapeutics, Inc. income tax expense (benefit) for fiscal 2023 was $0.00.
- Palvella Therapeutics, Inc. income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 3 month as first filed | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 6 month as first filed | Income Tax Expense (Benefit) 9 month | Income Tax Expense (Benefit) 9 month as first filed | Income Tax Expense (Benefit) 12 month | Income Tax Expense (Benefit) 12 month as first filed | Income Tax Expense (Benefit) 16 month |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-04 | $0.00 10-Q · filed 2026-08-04 | $0.00 derived: sum of 3 quarters · filed 2026-08-04 | $0.00 derived: sum of 4 quarters · filed 2026-08-04 | |||||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-07 | $0.00 derived: sum of 4 quarters · filed 2026-08-04 | |||||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $0.00 derived: sum of 2 quarters · filed 2026-03-31 | $0.00 derived: sum of 3 quarters · filed 2026-08-04 | $0.00 10-K · filed 2026-03-31 | |||||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2026-08-04 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 4 quarters · filed 2026-08-04 | |||||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-04 | $0.00 10-Q · filed 2026-08-04 | $0.00 derived: sum of 3 quarters · filed 2026-08-04 | $0.00 derived: sum of 4 quarters · filed 2026-08-04 | |||||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-07 | $0.00 derived: sum of 4 quarters · filed 2026-05-07 | |||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $0.00 derived: sum of 2 quarters · filed 2026-03-31 | $0.00 derived: sum of 3 quarters · filed 2026-03-31 | $0.00 10-K · filed 2026-03-31 | |||||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | ||||||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | |||||||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-15 | ||||||||
| 2023-12-31 | $0.00 10-K · filed 2025-03-31 | ||||||||
| 2022-12-31 | $0.00 10-K · filed 2024-03-29 | ||||||||
| 2021-12-31 | $0.00 10-K · filed 2023-03-31 | ||||||||
| 2020-12-31 | $164.00K 10-K · filed 2022-03-02 | ||||||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $0.00 derived: sum of 2 quarters · filed 2021-03-31 | $0.00 derived: sum of 3 quarters · filed 2021-03-31 | $0.00 10-K · filed 2021-03-31 | |||||
| 2019-09-30 | $0.00 10-Q · filed 2019-11-12 | $0.00 derived: sum of 2 quarters · filed 2019-11-12 | $0.00 10-Q · filed 2019-11-12 | -$164.00K derived: sum of 4 quarters · filed 2020-03-13 | |||||
| 2019-06-30 | $0.00 10-Q · filed 2019-08-09 | $0.00 10-Q · filed 2019-08-09 | -$164.00K derived: sum of 3 quarters · filed 2020-03-13 | -$164.00K derived: sum of 4 quarters · filed 2020-03-13 | |||||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-10 | -$164.00K derived: sum of 2 quarters · filed 2020-03-13 | -$164.00K derived: sum of 3 quarters · filed 2020-03-13 | -$312.00K derived: sum of 4 quarters · filed 2020-03-13 | |||||
| 2018-12-31 | -$164.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | -$164.00K derived: sum of 2 quarters · filed 2020-03-13 | -$312.00K derived: sum of 3 quarters · filed 2020-03-13 | -$312.00K 10-K · filed 2020-03-13 | |||||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-12 | -$148.00K derived: sum of 2 quarters · filed 2019-11-12 | -$148.00K 10-Q · filed 2019-11-12 | -$4.00K derived: sum of 4 quarters · filed 2019-11-12 | |||||
| 2018-06-30 | -$148.00K 10-Q · filed 2019-08-09 | -$148.00K 10-Q · filed 2019-08-09 | -$4.00K derived: sum of 3 quarters · filed 2019-08-09 | $142.00K derived: sum of 4 quarters · filed 2019-08-09 | |||||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-10 | $144.00K derived: sum of 2 quarters · filed 2019-05-10 | $290.00K derived: sum of 3 quarters · filed 2019-05-10 | $1.10M derived: sum of 4 quarters · filed 2019-05-10 | |||||
| 2017-12-31 | $144.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $290.00K derived: sum of 2 quarters · filed 2019-03-18 | $1.10M derived: sum of 3 quarters · filed 2019-03-18 | $1.10M 10-K · filed 2019-03-18 | |||||
| 2017-09-30 | $146.00K 10-Q · filed 2018-11-07 | $145.70K 10-Q · filed 2017-11-13 | $960.00K derived: sum of 2 quarters · filed 2018-11-07 | $959.00K 10-Q · filed 2018-11-07 | $959.41K 10-Q · filed 2017-11-13 | ||||
| 2017-06-30 | $814.00K 10-Q · filed 2018-08-09 | $813.71K 10-Q · filed 2017-08-11 | $814.00K 10-Q · filed 2018-08-09 | $813.71K 10-Q · filed 2017-08-11 | |||||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-10 | ||||||||
| 2016-12-31 | $162.00K 10-K · filed 2018-03-15 | $161.97K 10-K · filed 2017-03-30 | |||||||
| 2016-06-30 | $0.00 10-Q · filed 2016-08-11 | $0.00 10-Q · filed 2016-08-11 | $163.43K derived: sum of 3 quarters · filed 2017-05-15 | $203.87K derived: sum of 4 quarters · filed 2017-05-15 | |||||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-15 | $163.43K derived: sum of 2 quarters · filed 2017-05-15 | $203.87K derived: sum of 3 quarters · filed 2017-05-15 | $203.87K derived: sum of 4 quarters · filed 2017-05-15 | |||||
| 2015-12-31 | $163.43K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30 | $203.87K derived: sum of 2 quarters · filed 2017-03-30 | $203.87K derived: sum of 3 quarters · filed 2017-03-30 | $203.87K 10-K · filed 2017-03-30 | |||||
| 2015-09-30 | $40.44K 10-Q · filed 2016-11-10 | $40.44K derived: sum of 2 quarters · filed 2016-11-10 | $40.44K 10-Q · filed 2016-11-10 | $40.44K derived: sum of 4 quarters · filed 2016-11-10 | |||||
| 2015-06-30 | $0.00 10-Q · filed 2016-08-11 | $0.00 10-Q · filed 2016-08-11 | $0.00 derived: sum of 3 quarters · filed 2016-08-11 | $0.00 derived: sum of 4 quarters · filed 2016-08-11 | |||||
| 2015-03-31 | $0.00 10-Q · filed 2016-05-12 | $0.00 derived: sum of 2 quarters · filed 2016-05-12 | $0.00 derived: sum of 3 quarters · filed 2016-05-12 | $0.00 derived: sum of 4 quarters · filed 2016-05-12 | |||||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | $0.00 derived: sum of 2 quarters · filed 2016-03-23 | $0.00 derived: sum of 3 quarters · filed 2016-03-23 | -$18.00 10-K · filed 2016-03-23 | |||||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $0.00 derived: sum of 2 quarters · filed 2015-11-13 | -$18.00 10-Q · filed 2015-11-13 | $0.00 10-Q · filed 2014-12-12 | |||||
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | -$18.00 10-Q · filed 2015-08-13 | $0.00 10-Q · filed 2014-12-12 | ||||||
| 2014-03-31 | -$18.00 10-Q · filed 2015-05-14 | ||||||||
| 2013-09-30 | $0.00 10-Q · filed 2014-12-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |